Enterosgel®治疗成人腹泻型肠易激综合征的随机双盲安慰剂对照多中心研究
本研究为随机、双盲、安慰剂对照、多中心试验,计划从英格兰约30个初级和二级保健站点招募430名IBS-D患者。筛选期2周后,受试者随机接受Enterosgel®或安慰剂盲法治疗8周,随后开放标签Enterosgel®治疗8周。主要结局是8周盲法阶段中至少4周腹痛和粪便稠度应答的受试者百分比。
要点
- 首个大规模RCT评估Enterosgel®治疗IBS-D的有效性和安全性。
- 主要结局为盲法阶段至少4周腹痛和粪便稠度应答率。
- 设计包括8周盲法治疗和8周开放标签治疗,允许按症状调整剂量。
核心结论
- 该研究旨在测试Enterosgel®相比安慰剂在IBS-D症状治疗中的有效性和安全性。
研究设计与样本
- 随机、双盲、安慰剂对照、多中心研究,计划招募430名IBS-D患者,来自英格兰约30个初级和二级保健站点。
- 筛选期2周,盲法治疗8周,随后开放标签Enterosgel®治疗8周,之后返回标准护理,应答者8周后随访电话。
关键数值与推荐
- 主要结局指标为8周盲法阶段中至少4周腹痛和粪便稠度应答的受试者百分比。
- 次要结局包括粪便频率、粪便稠度、腹痛、腹胀、急迫感、充分缓解、问卷评分和急救药物使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Irritable bowel syndrome (IBS) with diarrhoea (IBS-D) is a common and chronic condition that can significantly impair quality of life. The emergence of new drugs for IBS-D has been slow and there is a need for new treatments, including drug-free treatments, which are easy to use and suitable for different patient groups. Currently available drug-free treatments include Enterosgel®, an intestinal adsorbent approved for use in IBS-D and acute diarrhoea and available over-the-counter in the UK and 30 countries worldwide. The aim of this randomised, double-blind, placebo-controlled, multi-centre study is to test the efficacy and safety of Enterosgel® compared to placebo in symptomatic treatment in IBS-D. METHODS/DESIGN: We will recruit 430 participants with IBS-D from approximately 30 primary and secondary care sites in England. Participants meeting the required abdominal pain and stool consistency criteria over a 2-week screening period will be randomly allocated to receive blinded treatment (Enterosgel® or placebo) for 8 weeks. This will be followed by an 8-week open-label treatment phase with Enterosgel®. Participants will be allowed to adjust their daily dosage during both phases based on their symptoms. Participants will then return to standard care and those who responded to treatment will receive a follow-up call 8 weeks later. Co-medication with loperamide will be permitted and use recorded. The primary outcome measure is the percentage of participants defined as responders for abdominal pain and stool consistency during at least 4 weeks in the 8-week blinded phase. Secondary outcome measures include stool frequency, stool consistency, abdominal pain, bloating, urgency, adequate relief, questionnaire scores and rescue medication use. Exploratory outcomes will be assessed in subsets of participants including qualitative and quantitative data on faecal microorganisms and biomarkers and gut-related measurements from magnetic resonance imaging data. DISCUSSION: This is the first large scale randomised controlled trial investigating Enterosgel® in IBS-D. A study design with blinded phase followed by an open-label phase was chosen to encourage participation and study completion. Demonstrating that Enterosgel® is effective and safe in IBS-D could encourage adoption by patients and healthcare professionals and foster future clinical trials assessing its use in related conditions. TRIAL REGISTRATION: ISRCTN17149988. Prospectively registered on 14 November 2017.
引用
- Kemppinen A, Howell C, Allgar V, et al. Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults. Trials. 2020. PMID: 32000822. doi:10.1186/s13063-020-4069-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。